About this trial
This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.
Eligibility criteria
Qualifiers
Patients with postoperative lung cancer who have clear histological or cytological diagnosis.
Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points.
The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range.
Disqualifiers
Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.
Trial design
Treatments tested in this trial
- Jiawei Bufei Tang granules
- Placebo